TScan Therapeutics Q3 revenue jumps

Tscan Therapeutics

12/11/2025 12:14

Overview

TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements

Net loss for Q3 2025 increased due to higher R&D expenses

Company reached FDA agreement on pivotal trial design for TSC-101

Outlook

Company expects cash reserves to fund operations into the second half of 2027

Enrollment in solid tumor trial paused to focus on preclinical development

Result Drivers

R&D EXPENSES: Research and development (R&D) expenses for the third quarter of 2025 were $31.7 million, compared to $26.3 million for the third quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration and License Revenue
$2.51 mln
Q3 Net Income
-$35.71 mln
Q3 Basic EPS
-$0.28
Q3 Income From Operations
-$37.05 mln
Q3 Operating Expenses
$39.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 79.7% above its November 11 closing price of $1.22

Press Release: ID:nGNX9WGD6S

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)